Navigation Links
Study: EBV Mononucleosis Risk Increased by Smoking and Family Size; polyDNA Recommends Gene-Eden-VIR Against the Latent EBV
Date:7/21/2013

Rochester, NY (PRWEB) July 21, 2013

A new study has shown that people living in large households or in families with smokers are at a significantly higher risk of Epstein Barr Virus (EBV) infection. EBV is well-known as the virus that can cause Mononucleosis, also known as the “kissing disease.”(1)

This rise in the risk of infection is due to the fact that smoking harms the immune system, allowing the EBV to attack the body and infect it more effectively. Further, people living in crowded homes have a higher chance of coming into contact with someone already infected with the virus. These crowded conditions can also lead to infectious mononucleosis since “Persons with infectious mononucleosis may be able to spread the infection to others for a period of weeks.” (CDC) (2)

The researchers wrote that “Environmental factors associated with socioeconomic status, such as household crowding or use of public transportation, could contribute directly to exposure risk. Suppressed immune function as a result of stress, poor nutrition, smoking, or other environmental exposures could increase susceptibility to infections given equal levels of exposure.” (1)

The CDC notes that “In the United States, as many as 95% of adults between 35 and 40 years of age have been infected.” And, “When infection with EBV occurs during adolescence or young adulthood, it causes infectious mononucleosis 35% to 50% of the time.” (2)

EBV establishes a lifelong dormant (latent) infection in some cells of the body's immune system and can lead to various diseases over time. How can an infected person help prevent the latent EBV from causing problems later in life?

polyDNA recommends that individuals concerned about the risk of EBV infection stop smoking. In addition, because EBV is so common, everyone should consider using Gene-Eden-VIR, a natural anti-EBV remedy, to boost the immune system against the latent virus.

Gene-Eden-VIR recently underwent a post marketing clinical study in which 70% of Gene-Eden-VIR users reported a reduction in viral symptoms.(3) The results of this study can seen here: http://www.cbcd.net/Gene-Eden-VIR-Clinical-Study.php

The key to your health is to reduce the level of latent viruses in your body to harmless levels.” – Dr. Hanan Polansky

To learn more about Gene-Eden-VIR and the Epstein Barr Virus, visit: http://gene-eden-kill-virus.com/EBV.php

References:

(1)    http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3661547/
(2)    http://www.cdc.gov/ncidod/diseases/ebv.htm
(3)    http://www.cbcd.net/Gene-Eden-VIR-Clinical-Study.php

###

polyDNA is a biotechnology company that develops dietary supplements using the unique scientific method developed by Dr. Hanan Polansky, which is based on Computer Intuition.

In addition to his unique scientific method, Dr. Polansky published the highly acclaimed scientific discovery, called Microcompetition with Foreign DNA. The discovery explains how foreign DNA fragments, and specifically, DNA of latent viruses, cause most major diseases.

polyDNA developed Gene-Eden-VIR, an antiviral natural remedy that helps the immune system kill latent viruses.

Read the full story at http://www.prweb.com/releases/2013/7/prweb10949092.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. New Study: Alcohol Drinkers May Face Long Term Health Issues
2. Beaumont Study: Nerve Stimulation Helps with Overactive Bladder
3. Study: Ipilimumab Shows Durable Responses But Low Overall Response Rate In Patients With Unresectable Or Metastatic Mucosal Melanoma
4. A pan-European study: Signs of motor disorders can appear years before disease manifestation
5. Study: Older Whooping Cough Vaccine More Effective
6. Study: Peer-referral programs can increase HIV-testing in emergency departments
7. Study: Patient openness to research can depend on race and sex of study personnel
8. Study: Brain makes call on which ear is used for cell phone
9. Study: HIV Infection Does Not Adversely Affect Outcomes of Liver Transplantation for Hepatocellular Carcinoma
10. Penn pilot study: Group of Bradford Co, Pa. residents concerned about health effects of hydrofracking
11. Great HealthWorks, Inc., makers of Omega XL, Report New Independent Study: Omega-3 DHA Protects Against Liver Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica ... Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs ... Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health ... of their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards ... at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 /PRNewswire/ ... Diabetes Tomorrow,s Leaders Scholarship is any indication, the future ... today online at www.diabetesscholars.org by the Diabetes ... stand in the way of academic and community service ... scholarship program since 2012, and continues to advocate for ...
Breaking Medicine Technology: